header

Medical Information Library

Explore facts and recommendations for pharmacological treatments for obesity.

Medical Information

PDF
Wegovy™ (semaglutide) injection Dosing – Guidelines

Learn more about the Wegovy™ Dosing Guidelines. Wegovy™ should be initiated at a dose of 0.25 mg once weekly for 4 weeks. The dose should be increased in 4-week intervals (0.25 mg, 0.5 mg, 1 mg, 1.7 mg) until the maintenance dose of 2.4 mg is reached.

 

Download

Medical Information

PDF
Current Recommendations for Weight-Loss Medications as Part of Obesity Management (IME content)

Explore a snapshot of why medication is a powerful tool in obesity management.

Medical information

PDF
Overview of Current and Emerging Weight-Loss Pharmacotherapies (IME content)

Review outcomes and warnings for weight-loss medications currently approved by the FDA.

Researching other disease states?

Find medical information and ask questions about diabetes, hemophilia and more at Novo Nordisk Medical.

Visit Site

Medical Information

PDF
Overview of the STEP Clinical Development Program for Wegovy™ (semaglutide) Injection

Learn more about Wegovy’s™ STEP 1-4 clinical trials. These trials were built to evaluate its safety and efficacy for weight management in adult patients living with obesity and weight-related comorbidities.

 

Download

Medical Information

PDF
STEP 1 Clinical Trial: Weight Management with Wegovy™ (semaglutide) Injection

See the results of a 68-week trial comparing weight loss while receiving Wegovy™ or placebo in 1961 adults with obesity or overweight.

 

Download

Medical information

PDF
STEP 2 Clinical Trial: Weight Management with Wegovy™ (semaglutide) Injection in Adults with Type 2 Diabetes

View the findings of a 68-week trial comparing Wegovy™ vs placebo vs semaglutide injection 1.0 mg in 1210 adults with overweight or obesity and Type 2 diabetes.

Download

Medical information

PDF
STEP 3 Clinical Trial: Weight Management with Wegovy™ (semaglutide) Injection and Intensive Behavioral Therapy (IBT)

See the outcomes of a 68-week trial comparing Wegovy™ vs placebo in combination with IBT in 611 adults with obesity or overweight and at least 1 weight-related comorbidity.
 

Download

We're ready to help.

Speak with a Novo Nordisk medical information specialist for real-time answers to your questions about obesity research and treatments.

Start Conversation

Medical information

PDF
STEP 4 Clinical Trial: Sustained Weight Management with Wegovy™ (semaglutide) Injection

Review the findings of a 68-week trial comparing sustained weight management in adults with obesity or overweight and at least 1 weight-related comorbidity while receiving Wegovy™ or placebo.

 

Download

Explore other libraries

Learn more about obesity research and care

footer

Questions about obesity research or other disease states?

Speak to a live medical information specialist or submit a question via our web form.

Start Conversation

For other therapeutic areas, visit our Novo Nordisk Medical website.

Visit Site

This content is intended for education only. Any unauthorized copying or distribution of this document or the information it contains is strictly prohibited.

 

Continue

You are now leaving the Novo Nordisk Obesity Scientific Exchange website.

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.

 

Continue